Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, +26

The Lancet

Hematological MalignancyLymphoid NeoplasiaOncologyImmunologyHematology +6

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Michael R. Grever, Omar Abdel‐Wahab, Leslie A. Andritsos, +38

Blood

Targeting MTHFD2 in acute myeloid leukemia

Yana Pikman, Alexandre Puissant, Gabriela Alexe, +18

The Journal of Experimental Medicine

Primary Aml BlastsHematological MalignancyMedicineAcute Myeloid LeukemiaCancer Cell Biology +8

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia

Versha Banerji, Stacey M. Frumm, Kenneth N. Ross, +17

Journal of Clinical Investigation

Cancer BiologyTumor BiologyAcute LeukemiaMyeloid NeoplasiaHematological Malignancy +16

On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells

Iris Gehrke, Eric D.J. Bouchard, Sara Beiggi, +4

Clinical Cancer Research

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Jeff P. Sharman, Versha Banerji, Laura Fogliatto, +25

Blood

High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort

Matthew D. Seftel, A Demers, Versha Banerji, +5

Leukemia Research

Hematological MalignancyLymphoid NeoplasiaEpidemiologyChronic Lymphocytic LeukemiaMedicine +10

SYK regulates mTOR signaling in AML

Julia Carnevale, Linda Ross, Alexandre Puissant, +5

Leukemia

Signal TransductionSignaling PathwayCellular BiochemistryMedicineCell Biology +3

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, +24

Blood

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

Matthew D. Seftel, John Kuruvilla, Tom Kouroukis, +16

Leukemia & lymphoma/Leukemia and lymphoma